NewLink, GSK get U.S. funding for faster development of Ebola vaccines

December 23, 2014 11:09 PM

15 0

(Reuters) - The U.S. Department of Health and Human Services (HHS) awarded contracts worth a total of about $43 million to NewLink Genetics Corp and GlaxoSmithKline Plc for faster development of two Ebola vaccines.

Under a $30 million contract, NewLink's unit BioProtection Systems Corp will conduct clinical trials to determine the lowest dose at which its vaccine generates an effective immune response, the HHS said.

Read more

To category page